{"schema_version":"1.0","type":"article","title":"康方雙抗闖美被退，FDA只認活多久","url":"https://drugnews.com.tw/articles/2026-11-17-akeso-summit-ivonescimab-fda-crl-overall-survival.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-17-akeso-summit-ivonescimab-fda-crl-overall-survival.md","lang":"zh-Hant","date":"2026-11-17","publish_at":"2026-11-17T08:00:00+08:00","updated_at":"2026-11-17","category":"商業分析系列","topic":"臨床與 CMC","tags":["Akeso","Summit Therapeutics","ivonescimab","FDA","PD-(L)1×VEGF"],"summary":"Summit於2026年11月15日公告收到ivonescimab完整回覆函；HARMONi主要OS分析p值0.057，未達0.0448的門檻。","key_points":["Summit於2026年11月15日公告收到ivonescimab完整回覆函；HARMONi主要OS分析p值0.057，未達0.0448的門檻。","康方原始授權總額最高50億美元；2024年擴區後累計簽約金5.15億美元，最高里程碑45.55億美元。","HARMONi-3鱗狀組PFS主要分析及早期OS期中分析預計2026年第四季進行；非鱗狀組2027上半年對應PFS分析。"],"facts":[{"claim":"Summit公告ivonescimab收到CRL","value":"2026-11-15","unit":"date","as_of":"2026-11-15","source":"https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx","note":"Summit原頁出現Cloudflare驗證，Business Wire原頁網路不可達；以FT同一公司新聞稿原文核對，不冒稱原頁開啟成功。"},{"claim":"HARMONi人數及中國收案","value":[438,273],"unit":"patients","as_of":"2025-09-07","source":"https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival"},{"claim":"HARMONi主要PFS惡化或死亡風險降低","value":48,"unit":"%","as_of":"2025-09-07","source":"https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival"},{"claim":"HARMONi主要OS死亡風險降低","value":21,"unit":"%","as_of":"2025-09-07","source":"https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival"},{"claim":"HARMONi主要OS p值與顯著門檻","value":[0.057,0.0448],"unit":"p","as_of":"2025-09-07","source":"https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival"},{"claim":"主要OS p值減顯著門檻","value":0.0122,"unit":"p","as_of":"2025-09-07","source":"https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival","note":"0.057-0.0448；p值距離本身不是療效量。"},{"claim":"HARMONi主要OS中位數（ivonescimab+化療、化療）","value":[16.8,14],"unit":"months","as_of":"2025-09-07","source":"https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival"},{"claim":"HARMONi後續事後OS分析HR及對應風險降低","value":[0.76,24],"unit":"HR; %","as_of":"2026-11-04","source":"https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2026/default.aspx","note":"事後分析、nominal結果，不取代原定主要OS分析。"},{"claim":"原始授權合約簽署及區域","value":"2022-12-05; US, Canada, Europe, Japan","unit":"date; territories","as_of":"2026-07-23","source":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm"},{"claim":"原始授權簽約金及總額上限","value":[500,5000],"unit":"USD million","as_of":"2026-07-23","source":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm","note":"原約；不與2024擴區後金額混用。"},{"claim":"2024擴區已付簽約金及新增商業里程碑","value":[15,55],"unit":"USD million","as_of":"2026-07-23","source":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm","note":"擴至Latin America, Middle East, Africa。"},{"claim":"擴區後累計簽約金、法規及銷售里程碑","value":[515,1050,3505],"unit":"USD million","as_of":"2026-07-23","source":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm"},{"claim":"擴區後最高剩餘里程碑及終生交易金額","value":[4555,5070],"unit":"USD million","as_of":"2026-07-23","source":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm","note":"1050+3505=4555；500+15+4555=5070。"},{"claim":"截至2026-06-30財報持續經營重大疑慮","value":"substantial doubt","unit":"financial statement","as_of":"2026-07-23","source":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm","note":"申報日2026-07-23；歷史截至日陳述不表示AZ投資後狀態不變。"},{"claim":"AZ投資金額、流通股及完全稀釋股權","value":[2000,12,10.6],"unit":"USD million; %; %","as_of":"2026-09-28／2026-10-05","source":"https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-announces-equity-investment-summit.html","note":"宣布2026-09-28；另以AZ2026-10-05官方頁核交割。"},{"claim":"Merck–LaNova簽約金及里程碑上限","value":[588,2700,3288],"unit":"USD million","as_of":"2024-11-14","source":"https://www.merck.com/news/merck-enters-into-exclusive-global-license-for-lm-299-an-investigational-anti-pd-1-vegf-bispecific-antibody-from-lanova-medicines-ltd/","note":"588+2700=3288。"},{"claim":"Pfizer–3SBio簽約金及里程碑上限","value":[1250,4800,6050],"unit":"USD million","as_of":"2025-05-19","source":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-licensing-agreement-3sbio","note":"1250+4800=6050；另100股權投資不納授權總額。"},{"claim":"BMS–BioNTech簽約金、確定付款及里程碑上限","value":[1500,2000,7600,11100],"unit":"USD million","as_of":"2025-06-02","source":"https://news.bms.com/news/details/2025/BioNTech-and-Bristol-Myers-Squibb-Announce-Global-Strategic-Partnership-to-Co-Develop-and-Co-Commercialize-Next-generation-Bispecific-Antibody-Candidate-BNT327-Broadly-for-Multiple-Solid-Tumor-Types/default.aspx","note":"1500+2000+7600=11100；BNT327靶點是PD-L1×VEGF-A。"},{"claim":"四筆目前合約總額上限加總","value":25508,"unit":"USD million","as_of":"2026-07-23","source":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm","note":"5070+3288+6050+11100=25508，另依參考7、8、13逐筆付款相加。"},{"claim":"sintilimab CRL日期及FDA建議","value":"2022-03-24; additional multiregional non-inferiority study with OS endpoint","unit":"date; recommendation","as_of":"2022-03-24","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-announces-complete-response-letter-sintilimab-combination"},{"claim":"Keytruda 2025全年產品銷售","value":31641,"unit":"USD million","as_of":"2026-02-03","source":"https://www.merck.com/news/merck-highlights-progress-advancing-broad-diverse-pipeline/","note":"只取Keytruda產品列；未併Qlex，刪去未證的適應症營收排名。"},{"claim":"HARMONi-3鱗狀與非鱗狀數據時程","value":"squamous primary PFS + early interim OS Q4 2026; non-squamous PFS H1 2027","unit":"planned analyses","as_of":"2026-11-04","source":"https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2026/default.aspx","note":"均為公司預期；未將PFS時程寫成確證OS。"},{"claim":"五項positive三期、2024-05中國核准及中國商業使用逾10萬","value":"5; 2024-05; >100000","unit":"trials; date; patients","as_of":"2026-11-15","source":"https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx","note":"positive依公司定義為至少一個預設主要終點達顯著，未稱HARMONi OS成功。"},{"claim":"AP505機制與授權","value":"PD-L1×VEGF; Tasly; Greater China excluding Taiwan","unit":"targets; licensee; territories","as_of":"2019-07-29","source":"https://www.apbioinc.com/news-detail12.htm"},{"claim":"HARMONi-2頭對頭PFS優勢","value":"HR 0.51; median 11.14 vs 5.82; p<0.0001","unit":"HR; months; p","as_of":"2024-09-08","source":"https://www.smmttx.com/wp-content/uploads/2024/09/2024_PR_0908_WCLC-HARMONi-2-Data-_-FINAL-7.pdf","note":"中國試驗、主要分析；不外推成美國已核准或不同適應症療效。"}],"sections":["01｜差在哪裡：0.057對0.0448","02｜FDA為什麼只認存活","03｜誰的錢卡住了","04｜真正的考試在年底","05｜台灣雙抗公司要讀的三件事","參考資料"],"references":[{"title":"Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application","source":"Summit Therapeutics","date":"2026-11-15","url":"https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx"},{"title":"Summit's global PD-1xVEGF data challenge regional consistency claims but show new promising survival trend","source":"Fierce Biotech","date":"2025-09-07","url":"https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival"},{"title":"Summit Therapeutics Form 10-Q（截至2026-06-30","source":"美國證管會","date":"2026-07-23","url":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm"},{"title":"FDA won't approve Summit, Akeso's ivonescimab","source":"pharmaphorum","date":"2026-11-15","url":"https://pharmaphorum.com/news/fda-wont-approve-summit-akesos-ivonescimab"},{"title":"Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy","source":"Eli Lilly","date":"2022-03-24","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-announces-complete-response-letter-sintilimab-combination"},{"title":"Merck Highlights Progress Advancing Broad, Diverse Pipeline","source":"Merck","date":"2026-02-03","url":"https://www.merck.com/news/merck-highlights-progress-advancing-broad-diverse-pipeline/"},{"title":"Merck Enters into Exclusive Global License for LM-299","source":"Merck","date":"2024-11-14","url":"https://www.merck.com/news/merck-enters-into-exclusive-global-license-for-lm-299-an-investigational-anti-pd-1-vegf-bispecific-antibody-from-lanova-medicines-ltd/"},{"title":"Pfizer Enters into Exclusive Licensing Agreement with 3SBio","source":"Pfizer","date":"2025-05-19","url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-licensing-agreement-3sbio"},{"title":"AstraZeneca announces strategic equity investment in Summit; completes investment","source":"AstraZeneca","date":"","url":"https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-announces-equity-investment-summit.html；https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-completes-equity-investment-in-summit-therapeutics.html"},{"title":"AP505大中華區（不含台灣）授權天士力","source":"圓祥生技","date":"2019-07-29","url":"https://www.apbioinc.com/news-detail12.htm"},{"title":"Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab","source":"Summit Therapeutics","date":"2024-09-08","url":"https://www.smmttx.com/wp-content/uploads/2024/09/2024_PR_0908_WCLC-HARMONi-2-Data-_-FINAL-7.pdf"},{"title":"Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026","source":"Summit Therapeutics","date":"2026-11-04","url":"https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2026/default.aspx"},{"title":"BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership for BNT327","source":"Bristol Myers Squibb","date":"2025-06-02","url":"https://news.bms.com/news/details/2025/BioNTech-and-Bristol-Myers-Squibb-Announce-Global-Strategic-Partnership-to-Co-Develop-and-Co-Commercialize-Next-generation-Bispecific-Antibody-Candidate-BNT327-Broadly-for-Multiple-Solid-Tumor-Types/default.aspx"}],"images":[{"alt":"ivonescimab與Keytruda作用機制","url":"https://drugnews.com.tw/assets/articles/akeso-summit-ivonescimab-fda-crl-overall-survival/figure-01.png"},{"alt":"HARMONi主要分析數據","url":"https://drugnews.com.tw/assets/articles/akeso-summit-ivonescimab-fda-crl-overall-survival/figure-02.png"},{"alt":"四筆交易的簽約金與總額上限","url":"https://drugnews.com.tw/assets/articles/akeso-summit-ivonescimab-fda-crl-overall-survival/figure-03.png"},{"alt":"ivonescimab授權、核准與臨床讀數時間線","url":"https://drugnews.com.tw/assets/articles/akeso-summit-ivonescimab-fda-crl-overall-survival/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/akeso-summit-ivonescimab-fda-crl-overall-survival/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-17）。康方雙抗闖美被退，FDA只認活多久。https://drugnews.com.tw/articles/2026-11-17-akeso-summit-ivonescimab-fda-crl-overall-survival.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"「Summit於2026年11月15日公告收到ivonescimab完整回覆函」有哪些關鍵變化？","a":"Summit於2026年11月15日公告收到ivonescimab完整回覆函；HARMONi主要OS分析p值0.057，未達0.0448的門檻。"},{"q":"「康方原始授權總額最高50億美元」有哪些關鍵變化？","a":"康方原始授權總額最高50億美元；2024年擴區後累計簽約金5.15億美元，最高里程碑45.55億美元。"},{"q":"「HARMONi-3鱗狀組PFS主要分析及早期OS期中分析預計2026年第四季進行」有哪些關鍵變化？","a":"HARMONi-3鱗狀組PFS主要分析及早期OS期中分析預計2026年第四季進行；非鱗狀組2027上半年對應PFS分析。"}]}